Home Health Care Illumina forms 15-year cancer sequencing deal with Roche

Illumina forms 15-year cancer sequencing deal with Roche

6
0
SHARE

Although it faced a setback earlier this month when regulators put the kibosh on its deal to acquire a rival company, genetic sequencing equipment maker Illumina will leave the J.P. Morgan Healthcare Conference with two new partnering deals under its belt.

The San Diego-based company and Swiss drug and diagnostics maker Roche said Monday that they had formed a partnership to increase availability of genomic testing to patients with cancers. The 15-year, non-exclusive partnership is meant to broaden adoption of distributable next-generation sequencing-based testing in oncology. Financial terms between Illumina and Roche were not disclosed.

In addition, Illumina partnered with Genomics England to offer whole-genome sequencing for up to 300,000 people over the next five years for the Genomic Medicine Service, part of England’s National Health Service, Genomics England said.

Under the agreement with Roche, Illumina will grant the company the right to develop and distribute in vitro diagnostic tests running on Illumina’s NextSeq 550Dx system and on future systems. Roche will also help develop new companion diagnostic claims for Illumina’s pan-cancer assay TruSight Oncology 500, also known as TSO 500, for drugs that Roche already markets and that are in its pipeline.

Roche is no stranger to next-generation sequencing. In June 2018, it paid $2.4 billion to acquire the remaining share of Foundation Medicine that it didn’t already own.

“This collaboration is uniquely positioned to improve medical value and clinical decision making globally by combining the unique capabilities of the Roche Group including Foundation Medicine with Illumina and will provide more patients with access to NGS to characterize their disease and identify the right treatment for them,” Roche Diagnostics CEO Thomas Schinecker said in a statement. “This builds upon our strategy of accelerating clinical research, streamlining workflows and expanding assay menus to broaden access to genomic data and lower barriers to routine use.”

Roche also markets the drug Rozlytrek (entrectinib), which along with its competitor, Bayer’s Vitrakvi (larotrectinib) works by targeting a genetic anomaly known as an NTRK fusion that can be detected through NGS. Rozlytrek also works against a mutation known as ROS1. The drug won Food and Drug Administration approval in August 2019 for any solid tumor that expresses an NTRK fusion and for ROS1-positive non-small cell lung cancer.

With respect to the deal with Genomics England, the organization said the goal was to establish the country as a leader in the use of genome sequencing as a routine component of medical care. The NHS Genomic Medicine Service and others will provide the samples. There is also an option to deliver up to 500,000 genome equivalents.

On Jan. 3, Illumina said it would call off a deal to buy Pacific Biosciences of California for $1.2 billion after the U.S. Federal Trade Commission moved to block the deal. PacBio specializes in long-read sequencing, while Illumina’s focus is on short-read sequencing. Nevertheless, the FTC said the deal would have been anti-competitive.

Photo: jxfzsy, Getty Images

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1 + nine =